A - Human Necessities – 61 – B
Patent
A - Human Necessities
61
B
A61B 5/0468 (2006.01) A61B 5/0432 (2006.01) G06F 17/00 (2006.01)
Patent
CA 2611570
The present invention relates to a novel approach to identifying and managing cardiac arrhythmogenic risks associated with prolongation and/or dispersion of ventricular repolarization. The arrhythmogenic risks may be, for example, congenital, acquired, or drug induced, such as drug- induced Long QT Syndrome. As described herein, arrhythmogenic risks encompass ectopic beats, sustained and/or non-sustained ventricular tachycardia, e.g., Torsades de Pointes and ventricular fibrillation, and torsadogenic risks and QT prolongation risks. Accordingly, the present invention also relates to a novel approach to identifying and managing torsadogenic risk, for example, congenital, acquired, and drug induced, including but not limited to the torsadogenic risk created by antiarrhythmic drugs and other classes of drugs. The present invention also relates to a novel approach to identifying and managing QT prolongation risk, for example, as it relates to congenital, acquired, and drug induced risk, including but not limited to the QT prolongation risk created by CNS active compounds, antihistamines, antimicrobi- als, and gastro-intestinal drugs, and other drug classes.
L'invention concerne une nouvelle approche permettant d'identifier et de gérer des risques arythmogènes cardiaques associés à la prolongation et/ou la dispersion d'une repolarisation ventriculaire. Ces risques arythmogènes peuvent être, par exemple, congénitaux, acquis ou induits par un médicament, tels que le syndrome QT long induit par un médicament. Lesdits risques arythmogènes décrits comprennent les extra-systoles, la tachycardie ventriculaire soutenue et/ou non soutenue, par exemple, les torsades de pointes et la fibrillation ventriculaire, les risques torsadogènes et les risques de prolongation QT. De ce fait, l'invention concerne une nouvelle approche permettant d'identifier et de gérer un risque torsadogène, par exemple, congénital, acquis ou induit par un médicament, notamment le risque torsadogène créé par des médicaments anti-arythmogènes et d'autres classes de médicaments. L'invention concerne une nouvelle approche permettant d'identifier et de gérer un risque de prolongation QT, par exemple, un risque congénital, acquis et induit par un médicament, notamment le risque de prolongation QT créé par des composés actifs CNS, des antihistamines, des agents antimicrobiens, des médicaments gastro-intestinaux et d'autres classes de médicaments.
Mccarthy Tetrault Llp
Solvay Pharmaceuticals Gmbh
LandOfFree
Torsadogenic risk management tool does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Torsadogenic risk management tool, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Torsadogenic risk management tool will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2007758